Profiel
Jens Bjørheim currently works at Zelluna ASA, as Chief Medical Officer.
Dr. Bjørheim also formerly worked at Pronova BioPharma ASA, as Medical Director from 2006 to 2008, AstraZeneca A, as Senior Medical Director-Oncology from 2013 to 2016, and Ultimovacs ASA, as Chief Medical Officer.
Dr. Bjørheim received his doctorate degree in 1999 from the University of Oslo and doctorate degree in 2003 from the University of Oslo.
Actieve functies van Jens Bjørheim
| Bedrijven | Functie | Begin |
|---|
Eerdere bekende functies van Jens Bjørheim
| Bedrijven | Functie | Einde |
|---|---|---|
AstraZeneca A/S (Denmark)
AstraZeneca A/S (Denmark) Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical medicines | Corporate Officer/Principal | 01-01-2016 |
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: OtherHealth Technology Develops, manufactures and markets omega-3-derived pharmaceuticals | Hoofd Techniek/Wetenschap/O&O | 01-01-2008 |
Ultimovacs ASA
Ultimovacs ASA Pharmaceuticals: MajorHealth Technology Develops novel peptide based therapeutic cancer vaccine | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Jens Bjørheim
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: OtherHealth Technology Develops, manufactures and markets omega-3-derived pharmaceuticals | Health Technology |
University of Oslo
University of Oslo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AstraZeneca A/S (Denmark)
AstraZeneca A/S (Denmark) Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical medicines | Health Technology |
Ultimovacs ASA
Ultimovacs ASA Pharmaceuticals: MajorHealth Technology Develops novel peptide based therapeutic cancer vaccine | Health Technology |
















